$23.85
+1.50 (+6.69%)
Open$23.80
Previous Close$22.35
Day High$24.50
Day Low$23.20
52W High$42.12
52W Low$10.01
Volume—
Avg Volume6.5K
Market Cap65.15M
P/E Ratio—
EPS$-18.93
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-48.0% upside
Current
$23.85
$23.85
Target
$12.39
$12.39
$7.78
$12.39 avg
$16.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 16.49M | 4.59M | 4.05M |
| Net Income | -21,225,483 | -196,564 | -196,089 |
| Profit Margin | -128.7% | -4.3% | -4.8% |
| EBITDA | -21,279,915 | -265,994 | -241,454 |
| Free Cash Flow | — | -252,687 | -239,821 |
| Rev Growth | — | +16.2% | +0.5% |
| Debt/Equity | 0.20 | 1.06 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |